Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale,...

Keywords

TicagrelorClopidogrelMedicinePercutaneous coronary interventionP2Y12Acute coronary syndromePrasugrelInternal medicineMyocardial infarctionPopulationClinical endpointCardiologyStroke (engine)Randomized controlled trial

Affiliated Institutions

Related Publications

Randomized Comparison of Prasugrel (CS-747, LY640315), a Novel Thienopyridine P2Y <sub>12</sub> Antagonist, With Clopidogrel in Percutaneous Coronary Intervention

Stephen D. Wiviott , Elliott M. Antman , Kenneth J. Winters +8 more

Background— Despite the current standard antiplatelet regimen of aspirin and clopidogrel (with or without glycoprotein IIb/IIIa inhibitors) in percutaneous coronary intervention...

2005 Circulation 378 citations

Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non–ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization

Lars Wallentin , Daniel Lindholm , Agneta Siegbahn +14 more

Background— Risk stratification and the use of specific biomarkers have been proposed for tailoring treatment in patients with non–ST-elevation acute coronary syndrome (NSTE-ACS...

2013 Circulation 109 citations

Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes

Lars Wallentin , Richard C. Becker , Andrzej Budaj +13 more

In patients who have an acute coronary syndrome with or without ST-segment elevation, treatment with ticagrelor as compared with clopidogrel significantly reduced the rate of de...

2009 New England Journal of Medicine 6927 citations

Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial Infarction

Shlomi Matetzky , Б. С. Шенкман , Victor Guetta +8 more

Background— Although clopidogrel reduces the risk of cardiovascular episodes after coronary events and stenting, a substantial number of incidents continue to occur. Methods and...

2004 Circulation 1352 citations

Dose Effect of Clopidogrel Reloading in Patients Already on 75-mg Maintenance Dose

Jean‐Philippe Collet , Johanne Silvain , Antoine Landivier +8 more

Background— Clopidogrel loading has mostly been studied in clopidogrel-naïve patients. Whether clopidogrel-treated patients readmitted for an acute coronary syndrome or percuta...

2008 Circulation 87 citations

Publication Info

Year: 2009
Type: article
Volume: 157
Issue: 4
Pages: 599-605
Citations: 398
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

398

OpenAlex

Cite This

APA Style

                            
                                
                                    Stefan James, 
                                
                                    Axel Åkerblom, 
                                
                                    Christopher P. Cannon
                                
                                et al.
                            
                            (2009). 
                            Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. 
                            American Heart Journal
                            , 157
                            (4)
                            , 599-605.
                            https://doi.org/10.1016/j.ahj.2009.01.003
                        

Identifiers

DOI: 10.1016/j.ahj.2009.01.003